Hikma Pharmaceuticals PLC (LON:HIK)
1,234.00
-15.00 (-1.20%)
Mar 5, 2026, 2:14 PM GMT
Hikma Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 217 | 188 | 205 | 270 | 426 |
Trading Asset Securities | - | 25 | 24 | 22 | 24 |
Cash & Short-Term Investments | 217 | 213 | 229 | 292 | 450 |
Cash Growth | 1.88% | -6.99% | -21.57% | -35.11% | 29.68% |
Accounts Receivable | 1,061 | 896 | 789 | 777 | 781 |
Other Receivables | 18 | 77 | 84 | 64 | 95 |
Receivables | 1,079 | 973 | 873 | 841 | 876 |
Inventory | 1,106 | 986 | 891 | 776 | 695 |
Prepaid Expenses | - | 73 | 72 | 74 | 65 |
Other Current Assets | 241 | 18 | 35 | 16 | 8 |
Total Current Assets | 2,643 | 2,263 | 2,100 | 1,999 | 2,094 |
Property, Plant & Equipment | 1,448 | 1,326 | 1,141 | 1,081 | 1,146 |
Long-Term Investments | 11 | 62 | 65 | 52 | 46 |
Goodwill | 393 | 382 | 388 | 389 | 285 |
Other Intangible Assets | 777 | 774 | 712 | 735 | 607 |
Long-Term Deferred Tax Assets | 307 | 293 | 226 | 192 | 183 |
Other Long-Term Assets | 92 | 33 | 48 | 23 | 11 |
Total Assets | 5,671 | 5,133 | 4,680 | 4,471 | 4,372 |
Accounts Payable | 715 | 358 | 309 | 291 | 262 |
Accrued Expenses | - | 439 | 388 | 272 | 305 |
Short-Term Debt | 14 | 21 | 46 | 75 | 64 |
Current Portion of Long-Term Debt | 92 | 621 | 104 | 64 | 48 |
Current Portion of Leases | 8 | 11 | 11 | 9 | 9 |
Current Income Taxes Payable | 74 | 78 | 74 | 73 | 57 |
Current Unearned Revenue | - | 28 | 21 | 193 | 213 |
Other Current Liabilities | 550 | 422 | 386 | 100 | 58 |
Total Current Liabilities | 1,453 | 1,978 | 1,339 | 1,077 | 1,016 |
Long-Term Debt | 1,445 | 607 | 975 | 1,074 | 651 |
Long-Term Leases | 45 | 46 | 55 | 61 | 74 |
Long-Term Unearned Revenue | - | 30 | - | - | - |
Long-Term Deferred Tax Liabilities | 16 | 18 | 25 | 19 | 24 |
Other Long-Term Liabilities | 106 | 133 | 77 | 92 | 140 |
Total Liabilities | 3,065 | 2,812 | 2,471 | 2,323 | 1,905 |
Common Stock | 40 | 40 | 40 | 40 | 42 |
Additional Paid-In Capital | 282 | 282 | 282 | 282 | 282 |
Retained Earnings | 2,556 | 2,362 | 2,158 | 2,092 | 2,189 |
Comprehensive Income & Other | -285 | -374 | -282 | -279 | -60 |
Total Common Equity | 2,593 | 2,310 | 2,198 | 2,135 | 2,453 |
Minority Interest | 13 | 11 | 11 | 13 | 14 |
Shareholders' Equity | 2,606 | 2,321 | 2,209 | 2,148 | 2,467 |
Total Liabilities & Equity | 5,671 | 5,133 | 4,680 | 4,471 | 4,372 |
Total Debt | 1,604 | 1,306 | 1,191 | 1,283 | 846 |
Net Cash (Debt) | -1,387 | -1,093 | -962 | -991 | -396 |
Net Cash Per Share | -6.23 | -4.89 | -4.33 | -4.41 | -1.70 |
Filing Date Shares Outstanding | 220.8 | 220.43 | 221.08 | 220.24 | 231.5 |
Total Common Shares Outstanding | 220.8 | 220.43 | 221.08 | 220.24 | 231.5 |
Working Capital | 1,190 | 285 | 761 | 922 | 1,078 |
Book Value Per Share | 11.74 | 10.48 | 9.94 | 9.69 | 10.60 |
Tangible Book Value | 1,423 | 1,154 | 1,098 | 1,011 | 1,561 |
Tangible Book Value Per Share | 6.44 | 5.24 | 4.97 | 4.59 | 6.74 |
Land | - | 851 | 797 | 725 | 676 |
Machinery | - | 1,067 | 1,042 | 964 | 934 |
Construction In Progress | - | 409 | 272 | 262 | 271 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.